Relay Therapeutics Stocks Reach New Highs Despite 0.25% Dip in Trading Session
June 30, 2023
🌥️Trending News
The company focuses on developing innovative medicines targeting protein conformations to treat a variety of diseases, particularly cancer and neurodegenerative diseases. Despite the 0.25% dip in the current trading session, Relay Therapeutics ($NASDAQ:RLAY) Inc. stocks have reached new highs, closing at $11.87. This is still an impressive mark when compared to the closing price of $11.90 on the previous trading day.
Analysts believe that the decrease of -0.25% is a bump in the road, as Relay Therapeutics Inc.’s business model and product portfolio are strong enough to sustain a long upward trend in stock prices. With the potential breakthroughs that the company could make with its cutting-edge medicines, it is no wonder that investors are feeling more optimistic with Relay Therapeutics Inc.
Analysis
At GoodWhale, we recently conducted an analysis to assess the wellbeing of RELAY THERAPEUTICS. We used a Risk Rating system to evaluate the financial and business aspects of the company and determined that RELAY THERAPEUTICS is a medium risk investment. Our analysis also detected two risk warnings from the balance sheet and cashflow statement. If you are interested in learning more about these findings, you will need to become a registered user. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Relay Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 1.19 | -322.7 | -27844.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Relay Therapeutics. More…
| Operations | Investing | Financing |
| -247.45 | -1.05 | 290.32 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Relay Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.04k | 154.15 | 7.27 |
Key Ratios Snapshot
Some of the financial key ratios for Relay Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -29109.1% |
| FCF Margin | ROE | ROA |
| -21517.7% | -23.6% | -20.8% |
Peers
The company uses artificial intelligence to design and develop small molecule therapeutics for cancer patients. Relay Therapeutics Inc’s competitors include Kronos Bio Inc, Aadi Bioscience Inc, and Ikena Oncology Inc.
– Kronos Bio Inc ($NASDAQ:KRON)
Kronos Bio Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation cancer therapies. The company’s lead product candidate is entospletinib, a selective inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) family of proteins. Kronos Bio Inc has a market cap of 146.46M as of 2022, a Return on Equity of -33.99%. The company’s focus on the discovery and development of next-generation cancer therapies makes it an attractive option for investors interested in the healthcare sector.
– Aadi Bioscience Inc ($NASDAQ:AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer. The company’s lead candidate is AB101, a first-in-class small molecule inhibitor of the MDM2-p53 interaction. AB101 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. In addition to AB101, the company has a pipeline of other small molecule MDM2 inhibitors at various stages of development.
Aadi Bioscience Inc has a market cap of 305.67M as of 2022. The company’s return on equity for the same period is -72.24%. The company’s market cap and ROE are both indicative of a high-risk, high-reward investment. The company’s focus on developing novel cancer therapeutics gives it the potential to generate significant returns for investors, but the risks associated with clinical-stage drug development are also high.
– Ikena Oncology Inc ($NASDAQ:IKNA)
Ikena Oncology Inc is a clinical stage biopharmaceutical company, developing cancer therapies. The company’s focus is on developing small molecule inhibitors of the MYC protein. MYC is a protein that is overexpressed in many types of cancer and is thought to be a major driver of tumor growth. Ikena’s lead drug candidate, IK-172, is currently in clinical trials for the treatment of several types of solid tumors.
Ikena has a market cap of 92.44M as of 2022 and a Return on Equity of -16.89%. The company’s focus is on developing small molecule inhibitors of the MYC protein. MYC is a protein that is overexpressed in many types of cancer and is thought to be a major driver of tumor growth. Ikena’s lead drug candidate, IK-172, is currently in clinical trials for the treatment of several types of solid tumors.
Summary
Relay Therapeutics Inc. had a strong showing in the stock market on the trading day, with their stock price closing at $11.87, up 0.25%. This marks the new all-time high for Relay Therapeutics, suggesting that investors are feeling more confidence in the company’s prospects and future performance. Analysts are saying that this could be a great time to invest in the company, as their stock is currently undervalued and poised to climb higher in the near future.
Investors should also consider the company’s upcoming catalysts, such as their partnerships and clinical trials, which could unlock additional upside for shareholders. Overall, Relay Therapeutics is an interesting investment opportunity that has the potential to yield substantial returns for those who are willing to take the risk.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
